Struggling Vaccines From Novartis Turn Into Sales Boon for GlaxoBy
Glaxo sees 2016 vaccine sales at nine times Novartis forecast
Meningitis shot Bexsero being studied as gonorrhea prevention
Outbreaks of the meningitis B disease in the U.S., along with the social-media frenzy that followed the death of a British toddler, have helped propel sales of GlaxoSmithKline Plc’s vaccine well past initial projections for its use.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.